文献速递其他结缔组织病

自体干细胞移植前后系统性硬化症抗拓扑异构酶I抗体分析

Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

结果显示移植后抗体反应性显著下降但多数患者仍保持阳性,且下降与临床结局不相关;移植前抗topo489-573抗体可能提示移植后病程较差。

要点

  • 自体干细胞移植后抗拓扑异构酶I抗体反应性显著下降,但多数患者随访24个月内仍为阳性。
  • 抗体反应性下降与移植后临床结局无相关性。
  • 移植前存在抗topo489-573抗体可能提示移植后病程较不理想。

核心结论

  • 自体干细胞移植是进展性系统性硬化症的良好治疗选择,但并不能消除针对拓扑异构酶I的抗体反应性。
  • 移植前存在抗topo489-573抗体可能提示移植后病程较不理想。

研究设计与样本

  • 在不同时间点共分析74份血清,采用ELISA检测针对全长topo I、截短topo I及覆盖氨基酸489-573的免疫优势表位的抗体。

主要发现

  • 自体干细胞移植后抗体反应性显著下降,但在随访至24个月的11例患者中仍有10例保持阳性。
  • 抗体下降与移植后临床结局无相关性。
  • 针对全长topo I或topo489-573的抗体反应性与移植前改良Rodnan皮肤评分或其移植后下降均无相关性。

临床怎么用

  • 对于接受自体干细胞移植的进展性系统性硬化症患者,不应期望移植能清除抗拓扑异构酶I抗体。
  • 移植前检测抗topo489-573抗体可能有助于提示移植后病程较不理想。

局限性

  • 未报告对照组或更长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of autologous stem cell transplantation (aSCTrans) on antibody (Ab) reactivity towards topo I in patients with SSc, and to see whether it may correlate with clinical outcome after aSCTrans. METHODS: Eighteen anti-topo/Scl70-positive patients with SSc in whom non-myeloablative aSCTrans had been performed were analysed. Seven patients showed good response without relapse for several years (group 1), eight primarily responded but later relapsed and three did not respond (group 2). A total of 74 sera were analysed at different time points and tested by ELISA against full length ( fl ) topo I, truncated ( tr ) topo I and a previously identified immunodominant epitope covering amino acid 489-573. RESULTS: Eighty-three percent had IgG Abs to topo fl and topo tr . Ab reactivity significantly decreased after aSCTrans, but remained positive in 10 of the 11 patients followed for up to 24 months. The decrease did not correlate with the clinical outcome after aSCTrans. Fifty-six percent of the patients reacted with topo489-573, and reactivity was nearly confined to group 2. There was no correlation between Ab reactivity towards topo fl or topo489-573 and the modified Rodnan Skin Score before aSCTrans or its decrease after aSCTrans. CONCLUSIONS: Although aSCTrans is a good treatment option in patients with progressive SSc, it does not abrogate Ab reactivity towards topo I. The presence of anti-topo489-573 Abs before aSCTrans may indicate a less favourable course after aSCTrans.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Henes J, Glaeser L, Kötter I, et al. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatology (Oxford). 2017. PMID: 27940597. doi:10.1093/rheumatology/kew319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。